BioNTech (NASDAQ:BNTX) shares are trading higher following news the company and Pfizer initiated a Biologics License Application with the FDA for approval of their mRNA vaccine. German government officials on Thursday also came out in opposition to Biden's plan to suspend COVID-19 vaccine patents, which has also helped lift the stock.
BioNTech's stock is trading up 7.15% to a price of $180.2. The stock's current volume for the day is 3.56 million, which is approximately 104.13% of its previous 30-day average volume of 3.42 million.
The stock's 50-day moving average was $126.98 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $213.15 and fallen to a low of $45.08.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.